Rethinking the Pharmaceutical Industry
A Worldwide View |
| |
| Program Overview |
| The
economics of the pharmaceutical industry and government policies in the
U.S., Japan and Europe are causing simultaneous contraction and
expansion in the industry. The mounting cost of research and
development and the increasing challenge of finding significant drugs
that can influence company growth are causing larger firms to merge or
rethink their business strategy. Government control of drug pricing
throughout the world is squeezing margins and forcing weaker companies
to merge. Meanwhile, a rich institutional investment community,
favorable government attitudes towards biomedical research, and the
lure of entrepreneurship are causing a proliferation of start-up
companies in the pharmaceutical field. Where will all this lead?
Leading industry authorities discuss this question at the 5th Annual
Philadelphia-Japan Health Sciences Dialogue. |
| |
| Welcome |
James E. Foley, Ph.D.
Vice President, Japan/International Business Development, Bristol-Myers Squibb Co. |
| |
| Welcome Remarks |
Masahiro Fukukawa
Deputy Consul General and Deputy Chief of Mission, Consulate General of Japan, New York |
| |
| Opening Remarks |
Leslie Hudson, Ph.D.
Vice Provost for Strategic Initiatives, University of Pennsylvania |
| |
| Keynote Address: Transforming R&D at Sankyo |
John C. Alexander, M.D., M.P.H.
President, Sankyo Pharma Development (USA)
Global Head of R&D, Sankyo Co. Ltd. (Japan) |
| |
Panel Discussion:
Investment Community Views on the Dynamics of the Pharmaceutical Industry |
Moderator: Peter A. Sears
Geoffrey Porges, M.D., Ph.D.
Senior Biotechnology Analyst, Sanford C. Bernstein & Co.
Phil Rowe
Executive Vice President, Capital Investment Research Inc.
Mary Tanner
Senior Managing Director, Bear, Stearns & Co. |
| |
Luncheon Keynote Address:
Rethinking Research & Development |
Ronald Krall, M.D.
Senior Vice President, Worldwide Development, GlaxoSmithKline
Greeting: Arlene Ashton
Deputy Secretary of International Business Development, Department of
Community and Economic Development, Commonwealth of Pennsylvania |
| |
Panel Discussion:
The Profound Influence of Government in Restructuring the Industry |
Gary Cooper
Senior Attorney, Goodwin Procter
Akira Miura
Director, Health and Welfare Department, JETRO New York
Theresa Mullin, Ph.D.
Assistant Commissioner for Planning, U.S. Food and Drug Administration |
| |
| The Proliferation of Biotech Companies: Wave of the Future or Total Madness? |
|
Brenda Gavin
Managing Partner, Quaker BioVentures
|
| |
| Networking Reception |
|
|
|